ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha W. Finney Sells 600 Shares

ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha W. Finney sold 600 shares of the company’s stock in a transaction on Monday, May 19th. The shares were sold at an average price of $138.92, for a total transaction of $83,352.00. Following the sale, the director now directly owns 3,252 shares in the company, valued at approximately $451,767.84. The trade was a 15.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ICU Medical Stock Down 2.2%

ICUI opened at $134.92 on Wednesday. ICU Medical, Inc. has a fifty-two week low of $100.91 and a fifty-two week high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The company has a fifty day moving average of $140.67 and a two-hundred day moving average of $153.48. The stock has a market capitalization of $3.32 billion, a price-to-earnings ratio of -29.52 and a beta of 0.87.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.49. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The company had revenue of $599.49 million during the quarter, compared to analysts’ expectations of $574.15 million. During the same quarter in the previous year, the company earned $0.96 earnings per share. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, research analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday. Raymond James dropped their target price on shares of ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating on the stock in a report on Friday, May 9th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research note on Tuesday, April 8th. Finally, KeyCorp decreased their price objective on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, ICU Medical presently has a consensus rating of “Buy” and a consensus target price of $192.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Arizona State Retirement System increased its holdings in ICU Medical by 1.0% in the 4th quarter. Arizona State Retirement System now owns 6,730 shares of the medical instruments supplier’s stock worth $1,044,000 after acquiring an additional 65 shares in the last quarter. Huntington National Bank increased its holdings in ICU Medical by 6.2% in the 4th quarter. Huntington National Bank now owns 1,402 shares of the medical instruments supplier’s stock worth $218,000 after acquiring an additional 82 shares in the last quarter. Equitable Trust Co. increased its holdings in ICU Medical by 1.6% in the 4th quarter. Equitable Trust Co. now owns 5,297 shares of the medical instruments supplier’s stock worth $822,000 after acquiring an additional 84 shares in the last quarter. Xponance Inc. increased its holdings in ICU Medical by 5.3% in the 1st quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier’s stock worth $238,000 after acquiring an additional 86 shares in the last quarter. Finally, LPL Financial LLC increased its holdings in ICU Medical by 2.0% in the 4th quarter. LPL Financial LLC now owns 4,816 shares of the medical instruments supplier’s stock worth $747,000 after acquiring an additional 93 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.